

*Review Article***Status of Research in the Field of Chemotherapy for Infectious Diseases in the Last 5 Years**

NUSRAT SHAFIQ\*, ASHISH KUMAR KAKKAR and SAMIR MALHOTRA

*Department of Pharmacology, PGIMER, Sector 12, Chandigarh 160 012, India*

(Received on 01 June 2017; Accepted on 03 October 2017)

The Indian National Science Academy has published two Status Reports on Pharmacological Research (1984 & 2000). The International Council for Science (ICSU) National Committee for Pharmacology has commissioned the third status report on Pharmacological Research in India covering the last 5 years. This report covers research done in chemotherapy of infectious diseases barring tropical diseases. The areas covered in chemotherapy included drug-discovery, observational studies, pharmacokinetics-pharmacodynamics and safety studies. We largely relied on Pubmed for our search. Work conducted in India and where at least one of the authors was affiliated to the Department of Pharmacology was included. Salient features of the studies were summarized. Lacunae in the current scene of research were explored and way forward suggested.

**Keywords:** Infections; Research; Status; Antimicrobials**Introduction**

The story of chemotherapy for infectious diseases is as interesting as the evolution of the concept of various kinds of microorganisms, invisible to the naked eye, causing diseases. Paul Ehrlich and Alexander Fleming are associated with modern history of antimicrobials (Aminov, 2010). Paul Ehrlich conceptualized the idea of *magic bullets* which would selectively kill pathogens without affecting host cells. The concept was based on his observations made on aniline and other synthetic dyes. He began his quest for magic bullets by screening compounds which could target syphilis. The sixth compound in the six hundredth series, compound 606, was salvarsan, the first antimicrobial against *Treponema pallidum*, developed through a process very similar to modern day screening procedures. This was in 1909. Close on its heels came prontosil, sulfonamidochrysoidine.

While the discovery of the above two categories of antimicrobials was through a systematic process, penicillin discovery was rather serendipitous. Interestingly, Fleming in his far reaching oversight had cautioned against the dangers of development of

resistance due to improper and excessive use of antimicrobials - "*The time may come when penicillin can be bought by anyone in the shops. Then there is the danger that the ignorant man may easily underdose himself and by exposing his microbes to non-lethal quantities of the drug make them resistant.*" (Fleming, 1945) Antimicrobial resistance has been an issue of concern since then. While the issue of rising incidence of resistance to first line agents for *Mycobacterium tuberculosis* predominated much of previous decade, resistance in other bacteria presents additional serious concerns of the present times. The need for newer antimicrobials is more evident now than ever before. While chemotherapeutic agents targeting bacteria were chased with waxing and waning vigour, diseases due to viruses and fungi started occupying the seats of attention.

While idoxuridine (Bauer, 1985), the first antiviral agent used to manage herpetic keratitis, made humble beginnings, some of the newer antiviral agents represent billion dollar markets (Gohil, 2014).

Rising use of antibacterials and

\*Author for Correspondence: E-mail: nusrat\_shafiq@hotmail.com

immunosuppressants brought along an increase in fungal infections. We now have an armamentarium of antifungals to choose from. However, development of resistance is posing increasingly familiar problems.

The aspects of chemotherapeutic agents for treating infections which needed to be researched went beyond discovery. The concept of pharmacokinetics-pharmacodynamics (PK-PD) and population pharmacokinetics (Pop-Pk) were recognized as extremely important not only for effective cure of infections but also for prevention of resistance (Riggs, 1997). Rational use of antimicrobials has needed constant oversight since antimicrobial use is directly correlated with the development of resistance. Safety has remained a concern since sulfinalimide elixir tragedy, wherein a new raspberry flavoured formulation of the antibiotic sulfanilamide led to the death of several children (Ballentine, 1981). Consequently, antimicrobial stewardship is now recognized as the need of the hour (Shafiq, 2016; Infectious Diseases Society of America, 2015; Doron and Davidson, 2011; Shafiq et al., 2017)

The Indian National Science Academy has published two Status Reports on Pharmacological Research (1984 & 2000). The International Council for Science (ICSU) National Committee for Pharmacology has commissioned the third status report on Pharmacological Research in India covering the last 5 years. The current report covers research done in the area of chemotherapy (excluding tropical diseases) in India.

## Methodology

We basically followed methodology described previously (Shafiq and Malhotra, INSA report on research in Clinical Pharmacology, 3017, *In press*). Briefly, we used various combinations of search terms to minimize redundancy and maximize the number of studies included as per the inclusion criteria. Various domains that were searched included – discovery; epidemiological studies such as drug utilization, questionnaire-based studies, studies answering practice related questions, pharmacoeconomics, pharmacogenomics; pharmacokinetics and/or pharmacokinetics-dynamics; safety/toxicity. The main source of information was PubMed. We used a filter of time limit of five years. In PubMed, use of this filter yielded articles from the year 2012 till the current

date. Search terms were varied to include “antimicrobials”, “antivirals”, “antifungals” and “antituberculosis” and “pharmacology” and “India”. In addition, a search was made keeping in mind some articles which may have appeared by the name of the disease, for example, “enteric fever”, “pneumonia”, “tuberculosis”, were used. Only 5 more articles satisfying inclusion criteria could be added to the initial search when searches were made with specific infections. Each of the search terms were combined with Pharmacology and India. Studies wherein the affiliations of at least one author to Pharmacology Department was reported were included. For excluding tropical diseases we used the WHO definition - “Tropical diseases encompass all diseases that occur solely, or principally, in the tropics. In practice, the term is often taken to refer to infectious diseases that thrive in hot, humid conditions, such as malaria, leishmaniasis, schistosomiasis, onchocerciasis, lymphatic filariasis, Chagas disease, African trypanosomiasis, and dengue.” (Tropical Diseases, 2017). The flow of studies is summarized in Fig 1.




Fig. 1: Flow of studies through various stages of screening and selection

## Discovery

A dwindling pipeline of antimicrobials in the wake of growing antimicrobial resistance is a major contemporary concern. Various approaches are used for screening purpose such as in-silico screening, synthesis of compounds using medicinal chemistry approach, tapping complementary and alternative medicine systems for potentially active compounds, novel formulations of existing antimicrobials and screening of antimicrobials from other naturally occurring pathogens. While the first two were explored to some extent, no research with the last approach could be identified. We also looked for novel concepts evaluated in a preclinical or clinical setting.

Evaluation of plant products for their antimicrobial use has been investigated. In a murine model of tuberculosis (Barua *et al.*, 2016), the antimycobacterial activity of *Alstonia scholaris* and *Mucuna imbricata* was evaluated. Methanolic extract of the former was found to be useful alone and in combination with rifampicin. In another study, 4-aminoquinolone piperidine amides were identified with potent cidal activity on *Mycobacterium tuberculosis*. Decaprenylphosphoryl- $\beta$ -D-ribose 2'-epimerase was identified as the primary target responsible for this activity (Naik *et al.*, 2014).

Using medicinal chemistry, novel esterquats (monoesterquats and diesterquats) were synthesized from 11-bromoundecanoic acid and different alkyl amines and their efficacy against gram positive bacteria and fungi was explored (Yasa *et al.*, 2016). Using similar approach, clavaminols were synthesized and some selected compounds were shown to have bactericidal as well as antifungal activity (Kumar *et al.*, 2016). Antibacterials and antifungal properties of congeners of 5-nitrofuranyl-triazole were evaluated (Kamal *et al.*, 2015). Derivatives of nitroimidazole compounds were evaluated for their efficacy against *Trichomonas vaginalis* (Mandalapu *et al.*, 2016) A library of sixty 2-methyl-4/5-nitroimidazole derivatives was synthesized and they were largely found to be more potent than metronidazole. This approach is in consort with contemporary approaches adopted in drug discovery for antimicrobials.

More specific targeting for identifying some leads in antimicrobials was undertaken for histone acetyltransferase Rtt109, a potential therapeutic

target in *Pneumocystis jirovecii* species (Sugumar *et al.*, 2016). Bioinformatics was used to find phytochemicals which could bind with the above targets. Baicalin was found to have good binding with the target site.

Modification of immune system for combating infections was explored. Atorvastatin, combined with imipenem, was shown to decrease bacterial load in an animal model of sepsis associated with lung injury (Adil *et al.*, 2015). The authors demonstrated an effect on inflammatory markers such as IL-1 $\beta$  and TNF $\alpha$  and MPO and ICAM-1 (Sood *et al.*, 2015). A similar immunomodulatory approach was evaluated for diarylheptanoids from *Alnus nepalensis* which was shown to attenuate LPS-induced inflammation in macrophages and endotoxic shock in mice (Saxena *et al.*, 2016). Daidzein, an isoflavone extract from soy, an inactive analog of the tyrosine kinase inhibitor genistein, showed a beneficial effect in preventing organ damage due to sepsis in a murine model (Parida *et al.*, 2015).

Development of novel formulations of existing drugs to provide therapeutic advantage was explored by some researchers. Some examples were corneal targeting of nanoformulation of netilmicin for decreasing frequency of administration (Chandasana *et al.*, 2014); inhaled microparticles for antitubercular drugs (Parikh *et al.*, 2014), nanoformulation of levofloxacin for sustained action against mycobacterial tuberculosis (Kumar *et al.*, 2012), a novel delivery system for intestinal targeting of ganciclovir (Mabrouk *et al.*, 2016), nanoformulation of darunavir for improving bioavailability (Bhalekar *et al.*, 2016), and sustained release nanoformulation of amphotericin B (Chhonker *et al.*, 2015).

In a clinical study for one of the complementary and alternative medicines, Qurse-e-istisqa (Q-e-I), a Unani medicine commonly prescribed to treat liver disorders, patients with HCV hepatitis were randomized to receive either standard of care alone or in combination with Q-e-I (Rehan *et al.*, 2015). The authors concluded that the medication did not affect viral replication but had anti-fibrotic effect. The study was found wanting in quality and the conclusions were not in consonance with the results.

Vi polysaccharide typhoid vaccines cannot be used in children <2 years owing to poor immunogenic

and T-cell independent properties (Mitra *et al.*, 2016). The vaccine was conjugated with tetanus toxoid to improve immunogenicity in children less than 2 years of age. A cluster randomized trial was undertaken to test the immunogenicity and efficacy of the vaccine. Vi conjugate typhoid vaccine conferred 100% protection against typhoid fever.

An interesting randomized controlled trial was conducted to evaluate the efficacy of ofloxacin alone and in combination with dexamethasone in chronic suppurative otitis media (Panchsara *et al.*, 2015). No difference was found between the groups and the authors concluded that dexamethasone use may be redundant. The study was recognized as a source of evidence for addressing an important practice-related question.

### **Epidemiological and Interventional Studies**

Various categories of studies were considered under this heading. These included prescription audits & drug utilization, questionnaire-based studies, studies exploring treatment regimens, pharmaco-economic and pharmacogenomic studies.

#### ***Prescription Audits and Drug Utilization***

Several studies were identified from various parts of the country. Though some of them were pertinent to the local practices, no study was identified which could be considered as sufficiently representative of practices in the country. Over-prescription of antibiotics was identified as a problem for non-bacterial diagnosis in a prescription audit of teaching and non-teaching hospitals in a Madhya Pradesh district (Landstedt *et al.*, 2017). In a retrospective analysis of in-patients with community acquired pneumonia done in Delhi, it was seen that there was an over-prescription of beta-lactams and beta-lactamase inhibitors and overall increase in patients being prescribed more than two antibiotics (Kotwani *et al.*, 2015). The authors emphasized the need for dissemination of guidelines for the management of pneumonia and the need for stewardship. In another observational study, done in uncomplicated upper respiratory tract infections, the authors observed a similar unnecessary use of antimicrobials (Kotwani and Holloway, 2014). Corroboration of correlation of antimicrobial resistance with antimicrobial consumption came from a JIPMER, Puducherry study. Valid

consumption and resistance data during the period Dec 2010 to Jun 2013 were obtained at 6-monthly intervals and resistance was found to correlate with antimicrobial consumption (Joseph *et al.*, 2015). A rather unexplored, albeit important area, was addressed in a study evaluating efficacy and safety of anti-tuberculosis drugs in HIV patients (Kapadia *et al.*, 2013). In HIV positive patients, association of anxiety and adherence to treatment was also noted in a small study (Panigrahi *et al.*, 2015).

In a prospective, questionnaire based study, investigators were able to garner the perceptions and opinions of clinicians on various aspects of antimicrobial misuse (Chatterjee *et al.*, 2015). The authors suggested that training of medical students and interns in rational antibiotic use, implementation of antibiotic policy, improvement in microbiology support and regular surveillance on this issue could be instrumental in tackling the problem of antimicrobial misuse. Drivers for antimicrobial use were explored in an interesting study from Vellore (Chandy *et al.*, 2013a). Perceived patient benefit, unrestricted autonomy and business-cum-industry pressures were found promoting inappropriate use of antibiotics.

Surveillance of antibiotic consumption in the community has always been a challenge. Undertaking periodic assessment of consumption at community level, a surveillance system was established (Chandy *et al.*, 2013b). Another area where considerable misuse of antimicrobials may be prevented was surgical prophylaxis as was noted in a retrospective analysis in a tertiary care hospital (Khan *et al.*, 2013)

With increase in multi-drug resistant infections, the use of polymyxins has increased considerably, as highlighted in an audit in a neonatal unit (Jasani *et al.*, 2015). Treatment issues for another emerging pathogen, *Burkholderia cepacia* complex were evaluated in a systematic review (Gautam *et al.*, 2015). Antimicrobial susceptibility data analysis showed a high incidence of resistance among uropathogens (Chatterjee *et al.*, 2016). Antibigrams were a source of information showing rising trend of vancomycin-resistant enterococci with nearly 24% isolates demonstrating resistance (Phukan *et al.*, 2016). Importantly, three of the isolates were found to be resistant to linezolid. Analysis of virulence and resistance mechanisms of *E. coli* isolates was

undertaken to throw light on pattern of transfer of resistance (Basu *et al.*, 2013). A horizontal transfer of resistance genes from pathogens to commensals occurring as a consequence of excessive antimicrobial use was highlighted.

Fixed-dose-combinations of antimicrobials have evoked special attention (Shafiq, 2016a). A retrospective study reported the effectiveness of a combination of ceftriaxone, sulbactam and EDTA (Patil and Jambulingappa, 2015). The purpose of conducting this analysis in eighteen patients was not clear and no remarkable conclusion could be deciphered. Various combinations of beta-lactams and beta-lactamase inhibitors are being used without evidence or with poor quality evidence. A prospective study showed the combination of cefotaxime/sulbactam and cefepime/sulbactam to be equally effective in the management of urinary tract infection (Kaur *et al.*, 2014). There are several issues with the study methodology, analysis and conclusions drawn. Similarly, many questions remain unanswered from a study based on *in vitro* susceptibility data comparing cefoperazone-sulbactam and cefoperazone-tazobactam (Patankar *et al.*, 2012).

### **Pharmacoeconomic Studies**

Economic burden of antimicrobial use is a topic of major concern. In an intensive care unit, the cost of treatment due to healthcare associated infections was Rs. 17,000 per patient and one-year cost 1 million rupees (Misal *et al.*, 2016). One study found Whitfield ointment plus oral fluconazole to be more cost-effective than topical 1% butenafine for tinea infections although the methodology for cost-effectiveness analysis was not elucidated (Thaker *et al.*, 2013).

### **Pharmacogenomics**

Pharmacogenomics has been infrequently evaluated in this field. The effect of variations in the N-acetyltransferase-2 gene on isoniazid metabolism showed 60% population (South Indian) comprised slow acetylators and the two-hour isoniazid concentrations differed significantly among three genotypes (Hemanth *et al.*, 2017).

### **Practice-related Issues**

An important aspect of antimicrobial use was evaluated in a prospective study undertaken to

compare surgical site infections in spinal surgeries following 24-hour versus 72-hour antimicrobial prophylaxis (Marimuthu *et al.*, 2016). No significant difference in surgical site infections was noted. In a randomized, controlled study, the need for antimicrobials for tooth extraction was investigated (Arora *et al.*, 2014). Three days of amoxicillin-clavulanic acid was not found to have any significant benefit over infection rates as compared to placebo given for the same duration. In another study answering a practice related query, a short course (3 days) of norfloxacin, co-trimoxazole and levofloxacin was shown to effectively achieve microbiological cure in patients with urinary tract infection (Vacchaani *et al.*, 2015). However, the study had several methodological and analytical issues and cannot be regarded as robust evidence to make a claim for short course of treatment with these antimicrobials for urinary tract infections. In a retrospective analysis of snake bite cases, it was noted that use of antibiotics is a common practice and ampicillin was the most commonly used antibiotic (Palapallil, 2015). The study made no attempts to address the need for antibiotics in snake bite, an issue which perhaps needs a nuanced addressal. Azithromycin as a treatment option for enteric fever was explored in a meta-analysis (Trivedi and Shah, 2012). In comparison to older fluoroquinolones, azithromycin was marginally better in reducing the chance of clinical failure (RR 0.46; 95% CI 0.25-0.82), while in comparison to ceftriaxone, it significantly reduced the chance of relapse (RR 0.1; 95% CI 0.01-0.76). Feasibility of management of neonatal sepsis in a community setting is an important issue. The same was addressed by means of a systematic review showing that combination regimens involving gentamicin may be a feasible option but the susceptibility patterns of pathogens responsible for the same may need a relook since data were from studies conducted over a decade ago (Jaiswal *et al.*, 2016).

### **Antimicrobial Stewardship**

While a 2014 communication by ICMR (Chandy *et al.*, 2014) highlighted the ICMR programme on antibiotic stewardship with an emphasis on the role of clinical pharmacologists in this exercise, only one original research from India could be identified wherein a stewardship model for resource-limited setting was evaluated. The authors demonstrated how

strategies of stewardship taking into consideration the practice-related situation in India could be used to bring down antimicrobial consumption and reduce irrational use of antibiotics (Shafiq *et al.*, 2016b).

### Pharmacokinetics

An important aspect of optimal use of antimicrobials is administration in a dose which maximizes the probability of attainment of adequate concentrations at the target site. Similarly, population pharmacokinetic studies are instrumental in delineating doses based on variables affecting drug disposition. Such studies were singularly missing. There were however, some studies which described pharmacokinetics or drug interactions of some antimicrobials. Plasma concentration monitoring of cefotaxime in critically ill patients in an intensive care unit showed a wide variability in pharmacokinetic parameters (Abhilash *et al.*, 2016). Some comparisons undertaken to explain this variability could not help in establishing pharmacodynamic response as a consequence of pharmacokinetic variability. The same authors also reported the pharmacokinetics of imipenem in critically ill patients but the study could not lead to any important conclusion regarding pharmacokinetics-pharmacodynamics (Abhilash *et al.*, 2015). Pharmacokinetics of colistin, although now better described than before, did not have data from our patient population. This was presented for the first time in a study done in critically ill patients with gram negative MDR infections (Karnik *et al.*, 2013). A wide inter-individual variability was noted, which is in consonance with earlier studies.

A pop-PK study of ceftriaxone-sulbactam was reported as a study done in healthy volunteers and infected individuals (Sharma *et al.*, 2016). However, the “infected individuals” part was only a simulation exercise. Weight was recognized as an important covariate and the conclusion was that 3g given every 24h is sufficient for bacteria with  $MIC \leq 8\mu\text{g/mL}$  while 3g every 12h is needed if MIC is 8-32 $\mu\text{g/m}$ .

Pharmacokinetics of antitubercular drugs was more extensively evaluated. In pediatric HIV-infected and non-infected population, it was noted that the 2-hour plasma levels of isoniazid, rifampicin and ethambutol were inadequate (Mukherjee *et al.*, 2016). The study made a case for revised higher doses of anti-tubercular drugs in children. While in this study

no difference between HIV-infected and non-infected children was seen, in another study, lower serum concentrations of rifampicin and pyrazinamide were found, and they were associated with poor treatment outcomes in children with tuberculosis related to HIV (Ramachandran *et al.*, 2016). Peak rifampicin and isoniazid concentrations were found to be inadequate in this study also. It was highlighted that rifampicin dose may not be adequate in pediatric population if administered according to RNTCP guidelines (Arya *et al.*, 2015). Inadequate levels of pyrazinamide in children were noted when given as recommended (Roy *et al.*, 2012). Correlation between higher rifampicin level and drug-induced hepatotoxicity was observed in a study (Satyaraddi *et al.*, 2014).

Drug levels of isoniazid and pyrazinamide in diabetics with TB were lower as compared to non-diabetics, which was attributed to delayed absorption and quicker elimination of these drugs (Kumar *et al.*, 2017).

Foraying into less travelled territories, the penetrability of intraocular penetration of oral moxifloxacin was compared to topical administration (Sharma *et al.*, 2015). Significantly higher levels in ocular fluids were seen after topical administration making it a suitable route of administration.

Only one drug interaction study was found (Rajagopalan *et al.*, 2013). Levofloxacin was found to significantly elevate lithium levels in rabbits.

### Safety

Adverse drug reactions and unwanted interactions represent negative consequences of antimicrobial pharmacotherapy that need to be detected, evaluated, and understood with the ultimate aim of their prevention and minimization of patient harm. Most commonly identified antibiotic related adverse reactions especially in critical care settings include anaphylaxis, nephrotoxicity, dermatological toxicity, diarrhea, hepatotoxicity and cytopenias (Granowitz and Brown, 2008). There were several isolated case reports of ADRs with specific antimicrobials (Garg *et al.*, 2015; Balaji *et al.*, 2014; Das *et al.*, 2014; Kameshwari *et al.*, 2014). However, these were not considered further due to lack of any systematic investigation into causes or frequency of occurrence. Similarly, several studies and systematic reviews

evaluated the occurrence of ADRs among people receiving pharmacotherapy in hospitals and/or in community settings (Geer *et al.*, 2016; Tandon *et al.*, 2015; Hiware *et al.*, 2013; Patel and Patel, 2016; Patel *et al.*, 2014; Patel *et al.*, 2013). Although antimicrobials were often found to be a major contributor to adverse reactions experienced by patients, these studies were not included since their primary focus was not on antimicrobial safety.

Several clinical studies compared the safety (and efficacy in some cases) of antimicrobials including combinations. A study in acne patients investigated the efficacy and safety of commonly prescribed topical preparations. Given the plethora of topical preparations available to dermatologists (keratolytics, antimicrobials, retinoids), this study compared clindamycin, benzoyl peroxide, nadifloxacin and topical tretinoin and found that benzoyl peroxide plus clindamycin was more efficacious, while benzoyl peroxide plus nadifloxacin was the safest (Kaur *et al.*, 2015).

A comparison of ofloxacin alone with ofloxacin plus dexamethasone in chronic suppurative otitis media found no difference in adverse events although steroid may have facilitated fungal colonization of external auditory canal (Panchasara *et al.*, 2015). Efficacy, safety and cost-effectiveness of triple drug regimens for *Helicobacter pylori* eradication showed that lansoprazole+tinidazole+clindamycin was efficacious and safe but clarithromycin+amoxicillin+omeprazole was the most cost-effective, although the authors failed to draw comparisons for efficacy/safety among the three regimens (Ghosh *et al.*, 2012).

An interesting retrospective study, conducted in HIV patients with cerebral toxoplasmosis, compared pyrimethamine/sulfadiazine (preferred regimen) with cotrimoxazole/clindamycin. In this study, the latter fared better more frequent achievement of complete response, lesser mortality and fewer adverse reactions (Goswami *et al.*, 2015). As per the authors this was the first study reporting the use of cotrimoxazole/clindamycin thereby overcoming the limitations imposed by pyrimethamine/ sulfadiazine (toxicity and consequent treatment withdrawal).

Renal safety of single high-dose amikacin was compared with gentamicin in combination with metronidazole for surgical prophylaxis. The study

showed both drugs to be associated with acute kidney injury (16% with amikacin versus 24% with gentamicin) within 1 week of administration although all patients had normal serum creatinine levels at one month (Giri *et al.*, 2016).

The impact of diabetes mellitus on treatment outcomes and safety of directly observed treatment, short-course (DOTS) strategy in tuberculosis patients showed that diabetics had higher sputum positivity at the end of intensive phase, poorer outcomes at the end of treatment, and more ADRs (restlessness, hypoglycemia, back pain, feet pain) compared with non-diabetics (Siddiqui *et al.*, 2016). An important limitation of this analysis was failure to rule out causal association with concomitant antidiabetic medications. A study evaluating safety of antitubercular treatment in HIV patients showed majority of ADRs were mild and were causally linked as possible or probable using Naranjo scale (Kapadia *et al.*, 2013).

A prospective study which analyzed the pattern of adverse drug reactions among patients who were prescribed antibiotics in the otolaryngology department of at a tertiary care hospital showed beta-lactams were the most frequently prescribed, diarrhea was the most common ADR, followed by neurotoxicity, cutaneous reactions, liver and renal ADRs, with elderly being at the greatest risk (Khan *et al.*, 2013). Another survey included children admitted to pediatric ward at a tertiary care hospital in eastern India (Baidya *et al.*, 2017). Nearly 80% received antimicrobials, majority being prescribed cephalosporins. The initial choice was usually empirical and median duration of treatment was 7 days. Most antimicrobials were prescribed parenterally and surprisingly only 2% children experienced any ADR. A study in HIV patients receiving antiretroviral regimens showed gender differences in ADRs with rash being more common in females while hypertriglyceridemia was seen predominantly in males (Rather *et al.*, 2013). Fear of ADRs as well as actual occurrence of ADRs were important causes for non-adherence to antiretroviral therapy (Panigrahi *et al.*, 2015).

A study on data collected under Pharmacovigilance Programme of India over three years at a tertiary care hospital found that nearly 15% of reported ADRs could be attributable to antimicrobials, with rash being the commonest and injectable ceftriaxone being the most commonly implicated antimicrobial, 90% of

ADRs were moderate in nature, a staggering 75% were probably and remaining possibly linked to antimicrobial drug therapy (Richa *et al.*, 2015).

## Discussion

The current report attempted to summarize the work done in the field of chemotherapy for infectious diseases barring tropical diseases mainly through PubMed search. The inherent nature of the topic posed limitations on search. Though an attempt was made to maximize the articles, it was not possible to cover all. Since the topic spanned bacterial, mycobacterial, viral and fungal infections, the routine principles of searching could not be adhered to. It is likely that some important articles have been missed out. Inferences could only be made based on the affiliations listed in 'author affiliations' section. If the affiliation of only the first or corresponding author was mentioned, then it could not be ascertained if any of the remaining authors was a pharmacologist. Such articles, however, were relatively few in number.

Discoveries in the field of antimicrobials had slackened worldwide in the previous decade due to several reasons of which compromised economic returns is extremely important. However, several initiatives by governments, particularly for drug discovery against resistant bacteria have been recently given a push (Leupke *et al.*, 2017). Two examples are, CARB-X (Combating Antimicrobial-Resistant Bacteria Biopharmaceutical Accelerator) and ND4BB (New Drugs for Bad Bugs). These are multi-disciplinary initiatives with pharmacologists needing to play important roles. Back home, such systematic initiatives from our funding agencies remain in the pipeline. Central Drug Research Institute is a standalone institute currently equipped with steering drug discovery in a holistic manner. More such institutes are required and perhaps some dedicated to the needs of discovery of drugs for resistant organisms.

It was interesting to note that the work on discovery of agents was dominated by specialists from allied branches such as pharmacy, chemistry, and bioinformatics. An increased role of pharmacologists in this area would be instrumental in directing discovery to translation for she/he will be able to understand myriad of issues that go into enabling a potential molecule to be converted into a viable drug

(Hughes and Karlen, 2014). Further, strangely, antimicrobials have been receiving attention from microbiologists. The same attention is missing from Pharmacologists when the fact remains that antimicrobials are groups of drugs which need a much nuanced approach involving different branches of pharmacology. It was encouraging to see that the approach of reformulating existing chemotherapeutic agents for improving therapy is growing and is getting refined.

As mentioned earlier, observational studies of various kinds were frequently published. What was lacking was holistic studies and a system for undertaking regular surveys for elucidating patterns of antimicrobial use. The role of pharmacologists in this area needs to increase several-fold. A group which will work in collaboration with the government machinery to develop this system is urgently needed. This need has been highlighted by the National Action Plan released by Government of India (National Action Plan 2017). While a lot of misuse of antimicrobials was recognized, interventional strategies for tackling it were rarely explored. It was interesting to note that beside the routine exercise of elaborating the defined daily doses (DDD), investigators explored pertinent issues such as – rationale, economic impact (albeit patchily), pharmacogenomics and drivers for prescription.

Antimicrobial stewardship, which recognizes the role of pharmacologists needs to be initiated in a big way (Chandy, 2015). While our group was able to model such a system in the institute (Shafiq *et al.*, 2016b), pharmacologists in other institutes need to train themselves in such an exercise and initiate similar services at their respective institutes. Pragmatic trials answering questions related to duration of therapy, optimal empiric/prophylactic regimens, doses are other areas where pharmacologists must generate data to provide evidence for best treatment.

PK-PD and pop-PK studies are extremely important in designing the dosage regimen of antimicrobials. A serious dearth of articles was found in this area, which should become the forte of pharmacologists. The reasons could be basic neglect of antimicrobials by pharmacologists and lack of resources (equipment, personnel, and funds) to undertake such studies. Antitubercular drugs received



a better treatment though. However, these studies were predominantly from a few centers. Since these studies are resource-intensive, overall compromised funding for health research may be an equally important reason for the paucity of studies.

Safety of antimicrobials is an important issue but despite an active pharmacovigilance program in the country, no remarkable studies could be found. Though case reports were not included for the current analysis, none of the publications could be considered as important in highlighting any novel adverse effect. Drug-induced liver injury, e.g., for antitubercular drugs, a commonly occurring problem, was largely unaddressed.

## References

- Abhilash B, Tripathi C D, Gogia A *et al.* (2016) Variability in plasma concentration of cefotaxime in critically ill patients in an Intensive Care Unit of India and its pharmacodynamic outcome: A nonrandomized, prospective, open-label, analytical study *J Pharmacol Pharmacother* **7** 15-21
- Abhilash B, Tripathi C D, Gogia A R *et al.* (2015) Pharmacokinetic/ pharmacodynamic profiling of imipenem in patients admitted to an intensive care unit in India: A nonrandomized, cross-sectional, analytical, open-labeled study *Indian J Crit Care Med* **19** 587-92
- Adil M, Kandhare A D, Dalvi G *et al.* (2015). Atorvastatin along with imipenem attenuates acute lung injury in sepsis through decrease in inflammatory mediators and bacterial load *Eur J Pharmacol* **2015** 447-56
- Aminov R L (2010) A brief history of the antibiotic era: lessons learned and challenges for the future *Frontiers Microbiol* **1** 1-7
- Arora A, Roychoudhury A, Bhutia O, *et al.* (2014). Antibiotics in third molar extraction; are they really necessary: A non-inferiority randomized controlled trial. *Natl J Maxillofac Surg.* **5** 166-71.
- Arya A, Roy V, Lomash A *et al.* (2015) Rifampicin pharmacokinetics in children under the Revised National Tuberculosis Control Programme, India, 2009 *Int J Tuberc Lung Dis* **19** 440-5
- Baidya S, Hazra A, Datta S *et al.* (2017) A study of antimicrobial use in children admitted to pediatric medicine ward of a tertiary care hospital *Indian J Pharmacol* **49** 10-15
- Balaji G, Maharani B, Ravichandran V *et al.* (2014) Linezolid induced black hairy tongue *Indian J Pharmacol* **46** 653-4
- Ballentine, Sulfanilamide Disaster, Taste of Raspberries, Taste of Death The 1937 Elixir Sulfanilamide Incident. Available at [www.fda.gov/AboutFDA/WhatWeDo/History/ProductRegulation/SulfanilamideDisaster/default.htm](http://www.fda.gov/AboutFDA/WhatWeDo/History/ProductRegulation/SulfanilamideDisaster/default.htm). Accessed 25<sup>th</sup> May 2017
- Barua A G, Raj H, Konch P *et al.* (2016) Evaluation of in vivo antimycobacterial activity of some folklore medicinal plants and enumeration of colony forming unit in murine model *Indian J Pharmacol* **48** 526-530
- Basu S, Mukherjee S K, Hazra A *et al.* (2013) Molecular Characterization of Uropathogenic Escherichia coli: Nalidixic Acid and Ciprofloxacin Resistance, Virulent Factors and Phylogenetic Background *J Clin Diagn Res* **7** 2727-31
- Bauer D J (1985) A history of discovery and clinical application of antiviral drugs *Br Med Bull* **41** 309-314
- Bhalekar M R, Upadhaya P, Madgulkar A *et al.* (2016) In-vivo bioavailability and lymphatic uptake evaluation of lipid nanoparticles of darunavir *Drug Deliv* **23** 2581-2586
- Chandasana H, Prasad Y D, Chhonker Y S *et al.* (2014) Corneal targeted nanoparticles for sustained natamycin delivery and their PK/PD indices: an approach to reduce dose and dosing frequency *Int J Pharm* **477** 317-25
- Chandy S, Mathai E, Thomas K *et al.* (2013a) Antibiotic use and resistance: perceptions and ethical challenges among doctors, pharmacists and the public in Vellore, South India *Indian J Med Ethics* **10** 20-7
- Chandy S J (2015) Antimicrobial resistance and inappropriate use of antimicrobials: Can we rise to the challenge? *Indian J Pharmacol* **47** 347
- Chandy S J, Michael J S, Veeraraghavan B *et al.* (2014) ICMR

- programme on Antibiotic Stewardship, Prevention of Infection & Control (ASPIC) *Indian J Med Res* **139** 226-30
- Chandy S J, Thomas K, Mathai E *et al.* (2013b) Patterns of antibiotic use in the community and challenges of antibiotic surveillance in a lower-middle-income country setting: a repeated cross-sectional study in Vellore, South India *J Antimicrob Chemother* **2013** 229-36
- Chatterjee D, Sen S, Begum S A *et al.* (2015) A questionnaire-based survey to ascertain the views of clinicians regarding rational use of antibiotics in teaching hospitals of Kolkata *Indian J Pharmacol* **47** 105-8
- Chatterjee N, Chatterjee C, Ghosh S *et al.* (2016) Pattern of Urinary Antibiograms in a Tertiary Care Hospital of Eastern India *J Assoc Physicians India* **64** 26-30
- Chhonker Y S, Prasad Y D, Chandasana H *et al.* (2015) Amphotericin-B entrapped lecithin/chitosan nanoparticles for prolonged ocular application *Int J Biol Macromol* **72** 1451-8
- Das A, Sil A, Mishra V *et al.* (2014) Steven's Johnson syndrome with toxic epidermal necrolysis due to thalidomide in a case of multiple myeloma *Indian J Pharmacol* **46** 557-9
- Doron S and Davidson L E (2011) Antimicrobial Stewardship *Mayo Clin Proc* **86** 1113-23
- Fleming A (1945) Penicillin-Nobel Lecture [https://www.nobelprize.org/nobel\\_prizes/medicine/laureates/1945/fleming-lecture.pdf](https://www.nobelprize.org/nobel_prizes/medicine/laureates/1945/fleming-lecture.pdf)
- Garg Y, Gore R, Jain S *et al.* (2015) A rare case of isoniazid-induced erythroderma *Indian J Pharmacol* **47** 682-4
- Gautam V, Shafiq N, Singh M *et al.* (2015) Clinical and in vitro evidence for the antimicrobial therapy in Burkholderia cepacia complex infections *Expert Rev Anti Infect Ther* **13** 629-6
- Geer M I, Koul P A, Tanki S A *et al.* (2016) Frequency, types, severity, preventability and costs of Adverse Drug Reactions at a tertiary care hospital *J Pharmacol Toxicol Methods* **81** 323-34
- Ghosh P, Kandhare A D, Gauba D *et al.* (2012) Determination of efficacy, adverse drug reactions and cost effectiveness of three triple drug regimens for the treatment of Helicobacter pylori infected acid peptic disease patients *Asian Pac J Trop Dis* **2** S783-9.
- Giri V P, Giri O P, Bajracharya S *et al.* (2016) Risk of Acute Kidney Injury with Amikacin versus Gentamycin both in Combination with Metronidazole for Surgical Prophylaxis *J Clin Diagn Res* **10** FC09-FC12
- Gohil K (2014) A huge growth seen in hepatitis C market *P n P* 2014 **3** 417
- Goswami R P, Goswami R P, Rahman M *et al.* (2015) Alternative treatment approach to cerebral toxoplasmosis in HIV/AIDS: experience from a resource-poor setting *Int J STD AIDS* **26** 864-9
- Granowitz E V and Brown R B (2008) Antibiotic adverse reactions and drug interactions *Crit Care Clin* **24** 421-442
- Hemanth K A K, Ramesh K, Kannan T *et al.* (2017) N-acetyltransferase gene polymorphisms & plasma isoniazid concentrations in patients with tuberculosis *Indian J Med Res* **145** 118-123
- Hiware S, Shrivastava M, Mishra D *et al.* (2013) Evaluation of Cutaneous Drug Reactions in Patients Visiting Out Patient Departments of Indira Gandhi Government Medical College and Hospital (IGGMC and H), Nagpur *Indian J Dermatol* **58** 18-21
- Hughes D and Karlen A (2014) Discovery and preclinical developments of new antibiotics *Ups J Med Sci* **119** 162-169
- Infectious Diseases Society of America (2015) Promoting antimicrobial stewardship in human medicine. Available from: [http://www.idsociety.org/Stewardship\\_Policy/](http://www.idsociety.org/Stewardship_Policy/) Accessed 16.06.2017
- Jaiswal N, Singh M, Kondel R *et al.* (2016) Feasibility and efficacy of gentamicin for treating neonatal sepsis in community-based settings: a systematic review *World J Pediatr* **12** 408-414
- Jasani B, Kannan S, Nanavati R *et al.* (2016) An audit of colistin use in neonatal sepsis from a tertiary care centre of a resource-limited country *Indian J Med Res* **144** 433-439
- Joseph N M, Bhanupriya B, Shewade D G *et al.* (2015) Relationship between Antimicrobial Consumption and the Incidence of Antimicrobial Resistance in Escherichia coli and Klebsiella pneumoniae Isolates *J Clin Diagn Res* **9**
- Kamal A, Hussaini S M, Sucharitha M L *et al.* (2015) Synthesis and antimicrobial potential of nitrofurantriazole congeners *Arg Biomol Che* **28** 4
- Kameswari P D, Selvaraj N and Adhimoalam M (2014) Fixed drug eruptions caused by cross-reactive quinolones *J Basic Clin Pharm* **5** 54-5
- Kapadia J D, Desai C K, Solanki MN *et al.* (2013) Efficacy and safety of anti-tuberculosis drugs in HIV-positive patients: a prospective study *Indian J Pharmacol* **45** 447-52
- Karnik N D, Sridharan K, Jadhav S P *et al.* (2013) Pharmacokinetics of colistin in critically ill patients with multidrug-resistant Gram-negative bacilli infection *Eur J Clin Pharmacol* **69** 1429-36

- Kaur J, Sehgal V K, Gupta A K *et al.* (2015) A comparative study to evaluate the efficacy and safety of combination topical preparations in acne vulgaris *Int J Appl Basic Med Res* **5** 106-10
- Kaur K, Gupta A, Sharma A *et al.* (2014) Evaluation of efficacy and tolerability of cefotaxime and sulbactam versus cefepime and tazobactam in patients of urinary tract infection-a prospective comparative study *J Clin Diagn Res* **8** HC05-8
- Khan A K A, P V M, Rashed M R *et al.* (2013). A Study on the Usage Pattern of Antimicrobial Agents for the Prevention of Surgical Site Infections (SSIs) in a Tertiary Care Teaching Hospital. *J Clin Diagn Res.* **4** 671-4
- Khan F A, Nizamuddin S, Huda N *et al.* (2013) A prospective study on prevalence of adverse drug reactions due to antibiotics usage in otolaryngology department of a tertiary care hospital in North India *Int J Basic Clin Pharmacol* **2** 548-53
- Kotwani A and Holloway K (2014) Antibiotic prescribing practice for acute, uncomplicated respiratory tract infections in primary care settings in New Delhi, India *Trop Med Int Health* **19** 761-8
- Kotwani A, Kumar S, Swain P K *et al.* (2015) Antimicrobial drug prescribing patterns for community-acquired pneumonia in hospitalized patients: A retrospective pilot study from New Delhi, India *Indian J Pharmacol* **47** 375-82
- Kumar A K, Chandrasekaran V, Kannan T *et al.* (2017) Anti-tuberculosis drug concentrations in tuberculosis patients with and without diabetes mellitus *Eur J Clin Pharmacol* **73** 65-70
- Kumar G, Sharma S, Shafiq N *et al.* (2012) Optimization, in vitro-in vivo evaluation, and short-term tolerability of novellefloxacin-loaded PLGA nanoparticle formulation *J Pharm Sci* **101** 2165-76
- Kumar V, Reddy V K, Jyotsna A *et al.* (2016) Total synthesis and in vitro bioevaluation of clavaminols A, C, H & deacetyl clavaminol H as potential chemotherapeutic and antibiofilm agents *Eur J Med Chem* **120** 86-96
- Landstedt K, Sharma A, Johansson F *et al.* (2017) Antibiotic prescriptions for inpatients having non-bacterial diagnosis at medicine departments of two private sector hospitals in Madhya Pradesh, India: a cross-sectional study *BMJ Open* **8** e012974
- Leupke K H, Suda K J, Boucher H *et al.* (2017) Past, present and future of antimicrobial economics: increasing bacterial resistance, limited antibiotic pipelines and societal implications *Pharmacotherapy* **37** 71-84
- Mabrouk M, Mulla J, Kumar P *et al.* (2016) Intestinal Targeting of Ganciclovir Release Employing a Novel HEC-PAA Blended Lyomatrix 4APS *Pharm Sci Tech* **17** 1120-30
- Mandalapu D, Kushwaha B, Gupta S *et al.* (2016) 2-Methyl-4/5-nitroimidazole derivatives potentiated against sexually transmitted Trichomonas: Design, synthesis, biology and 3D-QSAR study *Eur J Med Chem* **124** 820-839
- Marimuthu C, Abraham V T, Ravichandran M *et al.* (2016) Antimicrobial Prophylaxis in Instrumented Spinal Fusion Surgery: A Comparative Analysis of 24-Hour and 72-Hour Dosages *Asian Spine J* **10** 1018-1022
- Misal D D, Maulingkar S V and Bhonsle S (2016) Economic burden of antibiotic treatment of healthcare-associated infections at a tertiary care hospital ICU in Goa, India *Trop Doct* pii: 0049475516653068
- Mitra M, Shah N, Ghosh A *et al.* (2016) Efficacy and safety of vi-tetanus toxoid conjugated typhoid vaccine (PedaTyph™) in Indian children: School based cluster randomized study *Hum Vaccin Immunother* **2016** 939-45
- Mukherjee A, Velpandian T, Singla M, *et al.* (2016). Pharmacokinetics of isoniazid, rifampicin, pyrazinamide and ethambutol in HIV-infected Indian children. *Int J Tuberc Lung Dis.* **20** 666-72.
- Naik M, Humnabadkar V, Tantry S J *et al.* (2014) 4-aminoquinolone piperidine amides: noncovalent inhibitors of DprE1 with long residence time and potent antimycobacterial activity *J Med Chem* **57** 5419-34
- National Action Plan. Accessed at: <http://www.cseindia.org/userfiles/factsheet-national-actionplan.pdf> accessed 10.06.2017
- Palappallil D S (2015) Pattern of Use of Antibiotics Following Snake Bite in a Tertiary Care Hospital *J Clin Diagn Res* **9** OC05-9
- Panchasara A, Singh A, Mandavia D *et al.* (2015) Efficacy and safety of ofloxacin and its combination with dexamethasone in chronic suppurative otitis media. A randomised, double blind, parallel group, comparative study *Acta Otorhinolaryngol Ital* **35** 39-44
- Panigrahi M, Swain T R and Mohanty S (2015) Nonadherence to anti-HIV medication is associated with higher level of anxiety: Experience from a tertiary care hospital of Odisha *Indian J Pharmacol* **47** 672-5
- Parida S, Singh T U, Thangamalai R *et al.* (2015) Daidzein pretreatment improves survival in mouse model of sepsis *J Surg Res* **197** 363-73
- Parikh R, Dalwadi S, Aboti P *et al.* (2014) Inhaled microparticles of antitubercular antibiotic for in vitro and in vivo alveolar macrophage targeting and activation of phagocytosis *J Antibiot (Tokyo)* 2014

- Patankar M, Sukumaran S, Chhibba A *et al.* (2012) Comparative in-vitro activity of cefoperazone-tazobactam and cefoperazone-sulbactam combinations against ESBL pathogens in respiratory and urinary infections *J Assoc Physicians India* **60** 22-4
- Patel T K, Barvaliya M J, Sharma D *et al.* (2013) A systematic review of the drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Indian population *Indian J Dermatol Venereol Leprol* **79** 389-98
- Patel T K and Patel P B (2016) Incidence of Adverse Drug Reactions in Indian Hospitals: A Systematic Review of Prospective Studies *Curr Drug Saf* **11** 128-36
- Patel T K, Thakkar S H and Sharma D (2014) Cutaneous adverse drug reactions in Indian population: A systematic review *Indian Dermatol Online J* **5** S76-86
- Patil U N and Jambulingappa K L (2015) A Combination Strategy of Ceftriaxone, Sulbactam and Disodium Edetate for the Treatment of Multi-Drug Resistant (MDR) Septicaemia: A Retrospective, Observational Study in Indian Tertiary Care Hospital *J Clin Diagn Res* **2015** FC29-FC32
- Phukan C, Lahkar M, Ranotkar S *et al.* (2016) Emergence of vanA gene among vancomycin-resistant enterococci in a tertiary care hospital of North - East India *Indian J Med Res* **143** 357-61
- Rajagopalan S, Shafiq N, Pandhi P *et al.* (2013) Effect of levofloxacin on lithium - a pharmacokinetic study in rabbits *Fundam Clin Pharmacol* **27** 181-5
- Ramachandran G, Kumar A K, Kannan T *et al.* (2016) Low Serum Concentrations of Rifampicin and Pyrazinamide Associated with Poor Treatment Outcomes in Children with Tuberculosis Related to HIV Status *Pediatr Infect Dis J* **35** 530-4
- Rather Z A, Chowta M N, Raju G J K P *et al.* (2013) Evaluation of the adverse reactions of antiretroviral drug regimens in a tertiary care hospital *Indian J Pharmacol* **45** 145-8
- Rehan H S, Chopra D, Yadav M *et al.* (2015) Safety and efficacy of Qurse-e-istisqua in chronic hepatitis C infection: an exploratory study *Indian J Pharmacol* **47** 72-9
- Richa, Tandon V R, Sharma S *et al.* (2015) Adverse drug reactions profile of antimicrobials: A 3-year experience, from a tertiary care teaching hospital of India *Indian J Med Microbiol* **33** 393-400
- Riggs M M (1997) Population pharmacokinetics/pharmacodynamics and individualized drug therapy *J Am Pharm Assoc (Wash)* **1997** 59-6
- Roy V, Sahni P, Gupta P *et al.* (2012). Blood levels of pyrazinamide in children at doses administered under the Revised National Tuberculosis Control Program *Indian Pediatr* **49** 721-5
- Satyaraddi A, Velpandian T, Sharma S K *et al.* (2014) Correlation of plasma anti-tuberculosis drug levels with subsequent development of hepatotoxicity *Int J Tuberc Lung Dis* **18** 188-95
- Saxena A, Yadav D, Maurya A K *et al.* (2016) Diarylheptanoids from *Alnus nepalensis* attenuate LPS-induced inflammation in macrophages and endotoxic shock in mice *Int Immunopharmacol* **30** 129-36
- Shafiq N, Kumar G, Gautam V *et al.* (2016a) Fixed-dose combinations of antimicrobials: A need for special attention *Indian J Med Microbiol* **34** 208-9
- Shafiq N, M Kumar P, Kumar G *et al.* (2017) Antimicrobial Stewardship Program of Postgraduate Institute of Medical Education and Research: Running fast to catch the missing bus *JPMER* (Accepted in Press)
- Shafiq N, Praveen Kumar M, Gautam V *et al.* (2016b) Antibiotic stewardship in a tertiary care hospital of a developing country: establishment of a system and its application in a unit-GASP Initiative *Infection* **44** 651-9
- Shafiq N (2016) Time to rationalise, audit antibiotic use. Available at <http://www.tribuneindia.com/news/comment/time-to-rationalise-audit-antibiotic-use/307166.html> Accessed 25th May 2017
- Sharma T, Kamath M M, Kamath M G *et al.* (2015) Aqueous penetration of orally and topically administered moxifloxacin *Br J Ophthalmol* **99** 1182-5
- Sharma V D, Singla A, Chaudhary M *et al.* (2016) Population Pharmacokinetics of Fixed Dose Combination of Ceftriaxone and Sulbactam in Healthy and Infected Subjects *AAPS Pharm Sci Tech* **17** 1192-203
- Siddiqui A N, Khayyam K U and Sharma M (2016) Effect of Diabetes Mellitus on Tuberculosis Treatment Outcome and Adverse Reactions in Patients Receiving Directly Observed Treatment Strategy in India: A Prospective Study *Bio Med Res Int* 7273935
- Sood R, Raut R, Tyagi P *et al.* (2015) Cissampelos pareira Linn: Natural Source of Potent Antiviral Activity against All Four Dengue Virus Serotypes *PLoS Negl Trop Dis* **2015** 9
- Sugumar R, Adithavarman A P, Dakshinamoorthi A *et al.* (2016) Virtual Screening of Phytochemicals to Novel Target (HAT) Rtt109 in *Pneumocystis Jirovecii* using Bioinformatics Tools *J Clin Diagn Res* **10** FC05-8
- Tandon V R, Khajuria V, Mahajan V *et al.* (2015) Drug-induced diseases (DIDs): An experience of a tertiary care teaching hospital from India *Indian J Med Res* **142** 33-9

Thaker S J, Mehta D S, Shah H A *et al.* (2013) A comparative study to evaluate efficacy, safety and cost-effectiveness between Whitfield's ointment + oral fluconazole versus topical 1% butenafine in tinea infections of skin *Indian J Pharmacol* **45** 622-4

Trivedi N A and Shah P C (2012) A meta-analysis comparing the safety and efficacy of azithromycin over the alternate drugs used for treatment of uncomplicated enteric fever *J Postgrad Med* **58** 112-8

Tropical Diseases. Accessed at: [http://www.who.int/topics/tropical\\_diseases/en/](http://www.who.int/topics/tropical_diseases/en/)

Vachhani A V, Barvaliya M, Naik V *et al.* (2015) Effectiveness and tolerability of short course co-trimoxazole, norfloxacin and levofloxacin in bacteriological cure of uncomplicated urinary tract infection in outpatient setting. An open label, parallel group, randomized controlled trial *Infez Med* **23** 155-60

Yasa S R, Kaki S S, Poornachandra Y *et al.* (2016) Synthesis, characterization, antimicrobial and biofilm inhibitory studies of new esterquats *Bioorg Med Chem Lett* **2016** 1978-82.